Details for New Drug Application (NDA): 213407
✉ Email this page to a colleague
The generic ingredient in EMERPHED is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
Summary for 213407
| Tradename: | EMERPHED |
| Applicant: | Nexus |
| Ingredient: | ephedrine sulfate |
| Patents: | 5 |
Pharmacology for NDA: 213407
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
| Physiological Effect | Increased Norepinephrine Activity |
Medical Subject Heading (MeSH) Categories for 213407
Suppliers and Packaging for NDA: 213407
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407 | NDA | Nexus Pharamaceuticals Inc. | 14789-250 | 14789-250-10 | 10 VIAL in 1 CARTON (14789-250-10) / 10 mL in 1 VIAL (14789-250-07) |
| EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407 | NDA | Nexus Pharmaceuticals, LLC | 14789-251 | 14789-251-10 | 10 SYRINGE in 1 CARTON (14789-251-10) / 5 mL in 1 SYRINGE (14789-251-09) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 50MG/10ML (5MG/ML) | ||||
| Approval Date: | Apr 17, 2020 | TE: | AP1 | RLD: | Yes | ||||
| Patent: | 11,090,278 | Patent Expiration: | May 16, 2040 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION | ||||||||
| Patent: | 11,241,400 | Patent Expiration: | May 16, 2040 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION | ||||||||
| Patent: | 11,464,752 | Patent Expiration: | May 16, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
